Findings across SRI trials suggest that SRIs have a moderate-to-large treatment effect for treatment efficacy (g=0.50), and a moderate effect for treatment response (RR=1.80) and remission (RR=2.06). When examining treatment moderators of SRI trials, only methodological quality moderated treatment response. Thus, SRI trials with greater methodological rigor exhibited lower treatment response rates, which is likely attributed to reduced error variance in well-controlled medication trials. Interestingly, the difference between SSRI and CMI trended toward significance for both treatment efficacy (p=0.11) and treatment response (p=0.09) favoring CMI. Contrary to findings from individual SRI trials,[38; 44] TS/CTD and ADHD were not significant moderators of treatment efficacy, treatment response, or symptom/diagnostic remission. Although further examination is still warranted, this suggests that youth with TS/CTD or ADHD may still benefit from SRIs to treat their obsessive-compulsive symptoms.
